Press releases

Receive e-mail alerts

Internal link ProQR Announces Virtual Presentations at Scientific Conferences
September 24, 2020 at 08:10 PM UTC
Internal link ProQR to Participate in Upcoming Investor Conferences
September 03, 2020 at 11:00 AM UTC
Internal link ProQR Announces Second Quarter 2020 Operating and Financial Results
August 06, 2020 at 08:30 PM UTC
Internal link ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy
July 21, 2020 at 11:00 AM UTC
Internal link ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures
July 14, 2020 at 08:30 PM UTC
Internal link ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen
July 13, 2020 at 08:30 PM UTC
Internal link ProQR Announces Expert Perspectives Conference Call Series
June 12, 2020 at 11:00 AM UTC
Internal link ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)
June 08, 2020 at 11:00 AM UTC
Internal link ProQR Announces Annual Meeting of Shareholders
May 25, 2020 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2020 Operating and Financial Results
May 07, 2020 at 11:00 AM UTC
Internal link ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update
March 31, 2020 at 10:00 AM UTC
Internal link ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome
March 25, 2020 at 08:15 PM UTC
Internal link ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update
February 26, 2020 at 12:00 PM UTC
Internal link ProQR to Present at Cowen and Company 40th Annual Health Care Conference
February 24, 2020 at 12:00 PM UTC
Internal link ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases
February 06, 2020 at 12:00 PM UTC
Internal link ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a
January 30, 2020 at 12:00 PM UTC

Press releases

Internal link ProQR Announces Virtual Presentations at Scientific Conferences

Internal link ProQR to Participate in Upcoming Investor Conferences

Internal link ProQR Announces Second Quarter 2020 Operating and Financial Results

Internal link ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy

Internal link ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures

Internal link ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen

Internal link ProQR Announces Expert Perspectives Conference Call Series

Internal link ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)

Internal link ProQR Announces Annual Meeting of Shareholders

Internal link ProQR Announces First Quarter 2020 Operating and Financial Results

Internal link ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update

Internal link ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome

Internal link ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update

Internal link ProQR to Present at Cowen and Company 40th Annual Health Care Conference

Internal link ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases

Internal link ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a